Anthropic, a San Francisco-based artificial intelligence company valued at approximately $900 billion, has introduced Claude Code, its first AI product specifically designed for scientists and pharmaceutical organizations. The launch marks an effort by Anthropic to broaden its enterprise offerings and increase revenues ahead of a planned initial public offering (IPO), which is anticipated later this year and could value the company at over $11 trillion.
Claude Code aims to assist in areas such as rendering three-dimensional protein structures and accelerating drug discovery processes. Eric Kauderer-Abrams, Anthropic’s head of life sciences, highlighted that the company sees significant potential to positively impact humanity through advancements in the life sciences and healthcare sectors. “The primary purpose of releasing this product is to minimize the gap between what is currently possible with AI and what most scientists are accessing,” he said, emphasizing an ambition to elevate capabilities across diverse scientific disciplines.
This launch comes amid heightened scrutiny of Anthropic’s rapid growth and its AI models’ economic and security implications. The company’s Claude Mythos model, noted for its advanced cybersecurity capabilities, prompted U.S. officials to impose export controls before permitting limited deployment. Additionally, other Anthropic products such as Cowork—an AI agent aimed at non-technical users—have stoked concerns within software engineering, consulting, and legal industries about potential job displacement.
Claude Science, which operates on pre-existing Claude models, is expected to complement Claude Code by further expanding Anthropic’s suite of tools for scientific research. Kauderer-Abrams indicated that, while Claude Science could expedite early-stage drug discovery efforts, the company plans next to concentrate on solutions tailored for the clinical phases of drug development.
The pharmaceutical industry has increasingly integrated AI technologies, with major firms like Eli Lilly investing in computing infrastructure and AI-focused companies to enhance drug research and development. Anthropic has also strengthened its position in this space through partnerships with pharmaceutical companies and the acquisition of the biotech startup Coefficient Bio in April. Coefficient Bio had specialized in using AI to improve efficiency in biological research and drug discovery.
Anthropic’s renewed emphasis on scientific applications aligns with trends in the broader AI landscape, where competitors like OpenAI are also pursuing similar goals. OpenAI recently introduced GPT-Rosalind, a specialized reasoning model aimed at advancing scientific research and innovation.
As Anthropic moves toward its IPO, Claude Code and its related products could represent emerging revenue streams while aiming to deliver tangible benefits to the scientific and medical communities.